ATE238689T1 - ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT - Google Patents

ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT

Info

Publication number
ATE238689T1
ATE238689T1 AT00958855T AT00958855T ATE238689T1 AT E238689 T1 ATE238689 T1 AT E238689T1 AT 00958855 T AT00958855 T AT 00958855T AT 00958855 T AT00958855 T AT 00958855T AT E238689 T1 ATE238689 T1 AT E238689T1
Authority
AT
Austria
Prior art keywords
alpha
physiologically acceptable
intestinal absorption
amylase inhibitor
ßfast
Prior art date
Application number
AT00958855T
Other languages
German (de)
English (en)
Inventor
Nils Christian Mortensen
Original Assignee
Med Eq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Eq As filed Critical Med Eq As
Application granted granted Critical
Publication of ATE238689T1 publication Critical patent/ATE238689T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00958855T 1999-09-08 2000-09-08 ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT ATE238689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (1)

Publication Number Publication Date
ATE238689T1 true ATE238689T1 (de) 2003-05-15

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958855T ATE238689T1 (de) 1999-09-08 2000-09-08 ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT

Country Status (14)

Country Link
EP (1) EP1213972B1 (https=)
JP (1) JP2003508467A (https=)
KR (1) KR100594520B1 (https=)
AT (1) ATE238689T1 (https=)
AU (1) AU777044B2 (https=)
CA (1) CA2383720A1 (https=)
DE (1) DE60002484T2 (https=)
DK (1) DK1213972T3 (https=)
ES (1) ES2199174T3 (https=)
GB (2) GB9921229D0 (https=)
NO (1) NO314922B1 (https=)
NZ (1) NZ518167A (https=)
PT (1) PT1213972E (https=)
WO (1) WO2001017369A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
ITMI20052450A1 (it) * 2005-12-22 2007-06-23 Indena Spa Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス
US20100330137A1 (en) * 2008-03-10 2010-12-30 Mauro Mantovani High bioavailability formulation of mangosteen and manufacturing process thereof
CA2751227C (en) * 2009-02-02 2021-10-26 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
CN106686988A (zh) * 2014-09-19 2017-05-17 雀巢产品技术援助有限公司 用于降低伴侣动物碳水化合物吸收的方法和配制物
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.
AU2020281621B2 (en) * 2019-05-24 2025-09-11 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
WO2000043036A2 (en) * 1999-01-22 2000-07-27 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them

Also Published As

Publication number Publication date
CA2383720A1 (en) 2001-03-15
DK1213972T3 (da) 2003-08-18
GB9921229D0 (en) 1999-11-10
EP1213972B1 (en) 2003-05-02
DE60002484D1 (de) 2003-06-05
PT1213972E (pt) 2003-09-30
AU777044B2 (en) 2004-09-30
AU7026900A (en) 2001-04-10
EP1213972A1 (en) 2002-06-19
KR20020045605A (ko) 2002-06-19
ES2199174T3 (es) 2004-02-16
NO314922B1 (no) 2003-06-16
GB2364498A (en) 2002-01-30
KR100594520B1 (ko) 2006-07-19
NO20021160L (no) 2002-03-27
NO20021160D0 (no) 2002-03-08
NZ518167A (en) 2003-03-28
DE60002484T2 (de) 2004-03-18
GB0127158D0 (en) 2002-01-02
JP2003508467A (ja) 2003-03-04
WO2001017369A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
ATE238689T1 (de) ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT
DE69226624D1 (de) Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA2186380A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
BG105880A (en) Compounds useful as anti-inflammatory agents
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
HK1039745A1 (zh) 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶
AU3109502A (en) Method and composition for the treatment of diabetic neuropathy
AU2003295866A1 (en) Effervescent compositions
EP1068868A3 (en) Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
WO2003086271A3 (en) Azole derivatives as antifungal agents
GB9819317D0 (en) Organic compounds
GR3034142T3 (en) Composition for the treatment or prevention of herpes
PL357078A1 (en) A method for maintaining or improving the synthesis of mucins
YU58102A (sh) Postupak za održavanje ili poboljšanje sinteze mucina
DK0713485T3 (da) Thiocarbamoylforbindelser som mikrobicider

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1213972

Country of ref document: EP

REN Ceased due to non-payment of the annual fee